FOUNDATION OF BIOBRÁS
Researchers and entrepreneurs founded Biobrás to initially produce enzymes extracted from animal and vegetable raw materials. Focused on opportunities within the pharmaceutical industry, some of these enzymes were pepsin, bromelain, papain, trypsin, chymotrypsin and cellulases (microbial).
BRAZILIAN PIONEERING IN INSULIN PRODUCTION
Biobrás and Eli Lilly & Co (USA) form a joint venture for the production of insulin in Brazil. The crystals of insulin are produced in Montes Claros / MG and marketed worldwide. Biobrás is inspected and approved by the US FDA (Unites States Food and Drug Administration).
INJECTABLE INSULIN PRODUCTION
Biobrás purchases the participation of Eli Lilly & Co (USA) and develops highly purified insulins and formulating the injectable product, that is, ready for use.
Biobrás and the University of Brasilia have entered a partnership with the aim of developing the industrial production process of recombinant proteins, such as insulin.
PRODUCTION AND FORMULATION OF HIGHLY PURIFIED INSULINS
Biobrás becomes the 4th largest power in the world in the production of insulin, exporting to more than 20 countries.
RECOMBINANT HUMAN INSULIN PATENT
USPTO (United States Patent and Trademark Office) grants the title that ensures proprietary and exclusive use of recombinant human insulin to Biobrás.
We are the result of the spin-off of Biobras, acquired in 2001 by Novo Nordisk. In the operation, we inherited all the knowledge developed by the biopharmaceutical over 26 years. We have the expertise in industrial scale production of biotech products, intellectual property rights of the intellectual platform for production of recombinant proteins, researchers, executives and equipment used in the development of the insulin production process.
Our shares begin to be traded on the São Paulo Stock Exchange (Bovespa).
We have concluded exclusive agreements with 2 international laboratories: Gan & Lee (China) and Bioton (Poland), for the representation of medicines for the treatment of diabetes.
We announced an investment of R $ 330 million to build a factory in Nova Lima (MG), a land of 100 thousand m², with 12 thousand m² of built area and annual production capacity that reaches 20 million bottles of insulin and analogues.
INAUGURATION OF FACTORY AND GLOBAL PARTNERSHIPS
Nova Lima facility is inaugurated and two more exclusive agreements with foreign laboratories are signed: the North American MannKind Corporation, for the representation of medicine with rapid action for the treatment of diabetes, and South Korea Celltrion Healthcare, for cancer treatments.
1st REGISTERED PRODUCT ANVISA
approves Glargilin (insulin glargine), a long-acting insulin analogue.
ANVISA approves Herzuma (trastuzumab) and Afrezza (human insulin powder for inhalation)